Insulin Detemir Beats NPH at Blood Glucose Control


By: Daniel Trecroci

Blood glucose control with detemir, a long-acting insulin analog, is better than NPH insulin.

Insulin detemir, manufactured by Novo Nordisk and expected to be a competitor with the long-acting insulin glargine (Lantus), was studied in 408 people with type 1 diabetes for 16 weeks. Insulin detemir was administered twice daily using two different regimens: either before breakfast and at bedtime, or at 12-hour intervals.

NPH insulin was administered before breakfast and at bedtime.

In all treatment groups rapid-acting insulin was administered at mealtimes.

With both detemir-treated groups, fasting blood glucose (BG) improved. The 12-hour-interval group’s BGs were 27 mg/dl lower than the NPH-treated group’s, and the before-breakfast and bedtime-determir group was 40 mg/dl lower than the NPH-treated group.

The risk of minor hypoglycemia was lower in both detemir-treated groups.

Diabetes Care, May 2004



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.